Gast ::
| Hauptseite > Publikationsdatenbank > Design of human granzyme B variants resistant to serpin B9 > print |
| Hauptseite > Publikationsdatenbank > Design of human granzyme B variants resistant to serpin B9 > print |
| 001 | 201291 | ||
| 005 | 20240625095113.0 | ||
| 024 | 7 | _ | |a 10.1002/prot.24133 |2 doi |
| 024 | 7 | _ | |a 0887-3585 |2 ISSN |
| 024 | 7 | _ | |a 1097-0134 |2 ISSN |
| 024 | 7 | _ | |a WOS:000309456500003 |2 WOS |
| 024 | 7 | _ | |a altmetric:814073 |2 altmetric |
| 024 | 7 | _ | |a pmid:22733450 |2 pmid |
| 037 | _ | _ | |a FZJ-2015-03596 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 540 |
| 100 | 1 | _ | |0 P:(DE-HGF)0 |a Losasso, Valeria |b 0 |
| 245 | _ | _ | |a Design of human granzyme B variants resistant to serpin B9 |
| 260 | _ | _ | |a New York, NY |b Wiley-Liss |c 2012 |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1433837844_26781 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a article |2 DRIVER |
| 520 | _ | _ | |a Human granzyme B (hGB) is a serine protease involved in immune-mediated apoptosis. Its cytotoxicity makes it potentially applicable in cancer therapy. However, the effectiveness of hGB can be hampered by the cytosolic expression of a natural protein inhibitor, human Serpin B9 (hSB9). Here, we used computational approaches to identify hGB mutations that can affect its binding to hSB9 without significantly decreasing its catalytic efficiency. Alanine-scanning calculations allowed us to identify residues of hGB important for the interaction with hSB9. Some variants were selected, and molecular dynamic simulations on the mutated hGB in complex with hSB9 in aqueous solution were carried out to investigate the effect of these variants on the stability of the complex. The R28K, R201A, and R201K mutants significantly destabilized the interaction of the protein with hSB9. Consistently, all of these variants also retained their activity in the presence of the Serpin B9 inhibitor in subsequent in vitro assays of wild-type and mutated hGB. In particular, the activity of R201K hGB with and without Serpin B9 is very similar to that of the wild-type protein. Hence, R201K hGB emerges as a promising species for antitumoral therapy applications |
| 536 | _ | _ | |0 G:(DE-HGF)POF2-899 |a 899 - ohne Topic (POF2-899) |c POF2-899 |x 0 |f POF I |
| 588 | _ | _ | |a Dataset connected to CrossRef, juser.fz-juelich.de |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Schiffer, Sonja |b 1 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Barth, Stefan |b 2 |
| 700 | 1 | _ | |0 P:(DE-Juel1)145614 |a Carloni, Paolo |b 3 |e Corresponding Author |u fzj |
| 773 | _ | _ | |0 PERI:(DE-600)1475032-6 |a 10.1002/prot.24133 |g Vol. 80, no. 11, p. 2514 - 2522 |n 11 |p 2514 - 2522 |t Proteins |v 80 |x 0887-3585 |y 2012 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/201291/files/24133_ftp.pdf |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/201291/files/24133_ftp.gif?subformat=icon |x icon |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/201291/files/24133_ftp.jpg?subformat=icon-1440 |x icon-1440 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/201291/files/24133_ftp.jpg?subformat=icon-180 |x icon-180 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/201291/files/24133_ftp.jpg?subformat=icon-640 |x icon-640 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/201291/files/24133_ftp.pdf?subformat=pdfa |x pdfa |y Restricted |
| 909 | C | O | |o oai:juser.fz-juelich.de:201291 |p VDB |
| 910 | 1 | _ | |0 I:(DE-588b)1026307295 |6 P:(DE-HGF)0 |a German Research School for Simulation Sciences |b 0 |k GRS |
| 910 | 1 | _ | |0 I:(DE-588b)5008462-8 |6 P:(DE-Juel1)145614 |a Forschungszentrum Jülich GmbH |b 3 |k FZJ |
| 913 | 2 | _ | |0 G:(DE-HGF)POF3-899 |1 G:(DE-HGF)POF3-890 |2 G:(DE-HGF)POF3-800 |a DE-HGF |b Forschungsbereich Materie |l Forschungsbereich Materie |v ohne Topic |x 0 |
| 913 | 1 | _ | |0 G:(DE-HGF)POF2-899 |1 G:(DE-HGF)POF2-890 |2 G:(DE-HGF)POF2-800 |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |v ohne Topic |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF2 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0100 |2 StatID |a JCR |
| 915 | _ | _ | |0 StatID:(DE-HGF)0110 |2 StatID |a WoS |b Science Citation Index |
| 915 | _ | _ | |0 StatID:(DE-HGF)0111 |2 StatID |a WoS |b Science Citation Index Expanded |
| 915 | _ | _ | |0 StatID:(DE-HGF)0150 |2 StatID |a DBCoverage |b Web of Science Core Collection |
| 915 | _ | _ | |0 StatID:(DE-HGF)0199 |2 StatID |a DBCoverage |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |0 StatID:(DE-HGF)0200 |2 StatID |a DBCoverage |b SCOPUS |
| 915 | _ | _ | |0 StatID:(DE-HGF)0300 |2 StatID |a DBCoverage |b Medline |
| 915 | _ | _ | |0 StatID:(DE-HGF)0310 |2 StatID |a DBCoverage |b NCBI Molecular Biology Database |
| 915 | _ | _ | |0 StatID:(DE-HGF)1030 |2 StatID |a DBCoverage |b Current Contents - Life Sciences |
| 915 | _ | _ | |0 StatID:(DE-HGF)1050 |2 StatID |a DBCoverage |b BIOSIS Previews |
| 915 | _ | _ | |0 StatID:(DE-HGF)9900 |2 StatID |a IF < 5 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)GRS-20100316 |k GRS |l GRS |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)IAS-5-20120330 |k IAS-5 |l Computational Biomedicine |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)GRS-20100316 |
| 980 | _ | _ | |a I:(DE-Juel1)IAS-5-20120330 |
| 980 | _ | _ | |a UNRESTRICTED |
| 981 | _ | _ | |a I:(DE-Juel1)INM-9-20140121 |
| 981 | _ | _ | |a I:(DE-Juel1)IAS-5-20120330 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|